Regulatory
FDA Approves Regeneron’s Pasatru for Ultra-Rare ‘Stone Man Disease’
The antibody cut new abnormal bone formation by up to 90% in a trial for fibrodysplasia ossificans progressiva — a devastating disorder in which soft tissue slowly turns to bone.